Shekher Bose: Asundexian’s Targeted Factor XIa Inhibition May Transform Secondary Stroke Prevention Strategies
Shekher Bose, Client Partner at Beyondsight Intelligence, reposted Beyondsight Intelligence’s post on LinkedIn, adding:
”Asundexian’s targeted Factor XIa inhibition offers potent antithrombotic protection with a differentiated safety profile (minimal impact on hemostasis), potentially transforming care for millions worldwide and could pave the way for broader, safer secondary stroke prevention strategies—if approved.”
Quoting Beyondsight Intelligence‘s post:
”Bayer’s Asundexian Cuts Stroke Risk by 26%, No increase in major bleeding in Phase 3
Bayer reported positive topline results from the Phase 3 OCEANIC-STROKE trial evaluating asundexian (50 mg), an investigational once-daily oral Factor XIa inhibitor.
Key Highlights:
• 26% reduction in recurrent stroke risk vs placebo
• Studied in patients with prior non-cardioembolic ischemic stroke or high-risk TIA
• Added on top of standard antiplatelet therapy
• No increase in ISTH major bleeding vs placebo
• Designed for effective thrombosis prevention with a wider safety margin
Why It Matters:
• Current antithrombotics often require a trade-off between efficacy and bleeding risk
• Factor XI inhibition is emerging as a next-generation anticoagulation strategy
• Could enable safer long-term secondary stroke prevention
Key Takeaway:
Asundexian’s Phase 3 results suggest meaningful stroke risk reduction without the usual bleeding penalty—potentially reshaping the future of antithrombotic therapy.
Follow our page for more such updates.
News Source Demonstrated a Substantial Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack With No Increase in ISTH Major Bleeding Versus Placebo”
Stay updated with Hemostasis Today.
-
May 11, 2026, 01:38Heghine Khachatryan: The Emerging Era of Immunothrombosis and Precision Vascular Medicine
-
May 10, 2026, 18:07Recurrent DVT and PE in Young Adults May Indicate an Underlying Cause – The Lancet Group
-
May 10, 2026, 18:06Noemi Zampatti: Pediatric Celiac Crisis Complicated by Refeeding Syndrome and Proposed Diagnostic Criteria
-
May 10, 2026, 18:05Giovanni Solimeno: When the Common Femoral Artery Wall is Diseased, Closure is Not a Step
-
May 10, 2026, 18:04Maitri Vaishnav: The Bombay Blood Group and the Critical Role of the H Antigen
-
May 10, 2026, 18:03Nicolas Hubacz: Mesenchymal Stem Cells Are Some of the Most Fascinating Cells in Regenerative Medicine
-
May 10, 2026, 16:20Joshua Ngimbwa: How Sex and Socioeconomic Factors Influence Stroke Outcomes in Tanzania
-
May 10, 2026, 16:18Gustavo Monnerat: How Thousands of Fake References Slipped Into Biomedical Literature
-
May 10, 2026, 16:13Dalius Jatužis: Our AI-Driven Automated Stroke Registry Data Extraction Gets Best Poster Award at ESOC 2026